GlaxoSmithKline Pharmaceuticals share price
NSE: GLAXOBSE: 500660Pharmaceuticals & BiotechnologyMid Cap
GlaxoSmithKline Pharmaceuticals Limited · Formerly Glaxo (India) · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jan 1969 on BSE, Dec 2000 on NSE
Last close ₹2,498.00up ₹25.60 (1.04%)BSE ₹2,496.65
Share price at the NSE close on 28 Oct 2026. Previous close ₹2,472.40.
28 Oct: open ₹2,469.90, high ₹2,515.00, low ₹2,442.00
52-week range of traded prices to 28 Oct 2026
₹2,088.10Low, 12 Jun 2026₹3,120.70High, 28 Aug 2026
- Next results date: the board meets on 3 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹42,318 Cr221st largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 39.62
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 18.66
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 2.28%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 50.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 56.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 24,84257.5% delivered
About GlaxoSmithKline Pharmaceuticals
GlaxoSmithKline Pharmaceuticals Limited is the Indian subsidiary of GSK plc, a UK-based healthcare group, and sells medicines and vaccines in India.1 It works in general medicines such as antibiotics and skin treatments, in vaccines for children and adults, and in specialty medicines for respiratory disease and cancer.21 It makes tablets and skin products at its own plant in Nashik, Maharashtra, and also uses contract manufacturers across India.312
It was incorporated in 1924 and has been listed in India since 1969.42 It absorbed SmithKline Beecham Pharmaceuticals (India) Limited and Burroughs Wellcome (India) Limited by amalgamation, issuing shares for them in November 2001 and October 2004.5 It reports a single business segment, pharmaceuticals, and has a wholly owned subsidiary, Biddle Sawyer Limited.67 It had 3,103 permanent employees in India at March 2026.8
Its ultimate holding company is GSK plc.7 Glaxo Group Limited (35.99%), GlaxoSmithKline Pte Limited (28.10%), Eskaylab Limited (6.94%) and Burroughs Wellcome International Limited (3.97%) together hold 75.00% of its shares.59
GlaxoSmithKline Pharmaceuticals key points
Results
- In the quarter to Jun 2026, standalone revenue rose 15% to ₹924 crore, a softer base a year earlier adding roughly 4% to 5%, the company said; EBITDA (earnings before interest, tax, depreciation and amortisation) was ₹293 crore, a 31.7% margin.1011
- Standalone profit after tax was ₹253 crore, up 24%; the company said growth would have been about 17% without a one-off dividend from its subsidiary Biddle Sawyer Limited.1213
- In the year to Mar 2026, standalone revenue from operations rose 2% to ₹3,790 crore and the EBITDA margin widened by 290 basis points to 34.3%.14
- Standalone profit after tax before one-off items crossed ₹1,000 crore for the first time, and profit before tax on that basis rose 10% to ₹1,374 crore.15
Market position
- In the year to Mar 2026 it ranked 1st in private vaccines and dermatology, 2nd among multinational drug makers in India by value and 5th in acute (short-term illness) therapies by volume.16
- In the quarter to Jun 2026, its brands held 23% of their represented market (the market segments in which its brands compete), its general medicines 22% and its vaccines 27%.17
- Its antibiotic Augmentin was India's number 3 pharmaceutical brand in the year to Mar 2026; 7 of its brands were in the market's top 100 and 15 sold over ₹1,000 million a year.1819
- Its paracetamol brand Calpol held nearly one-third of India's paracetamol market in the year to Mar 2026.20
Products and pricing
- Newer products (cancer drugs Jemperli and Zejula, respiratory drugs Nucala and Trelegy, shingles vaccine Shingrix) made up 7% of sales in the quarter to Jun 2026, against 4% a year earlier.21
- In the year to Mar 2026, vaccine sales grew 11%, led by children's and adult vaccines, while key general medicine brands grew 2%.22
- The company said almost 44% to 45% of its general medicines portfolio is under price control (government caps on the prices of listed essential medicines).23
Plants and capacity
- Its Nashik plant makes about 4.8 billion tablets and 150 million tubes a year; the company reported 9.8 billion unit doses manufactured in the year to Mar 2026.2425
- In the year to Mar 2026 a fire at a contract manufacturer affected supply of key products; the company said the disruptions had a material impact on performance and it is diversifying suppliers.2426
Sales force and reach
Research and development
- In the year to Mar 2026 it had 26 global and local clinical trials ongoing or planned in India, in areas including cancer, malaria, hepatitis B and MASH (a fatty liver disease).3031
- On its earnings call of 3 Aug 2026, the company said regulators had approved Blenrep for multiple myeloma (a blood cancer) at second line, after one earlier treatment, and Arexvy, an adult vaccine against respiratory syncytial virus.3230
- In the year to Mar 2026 its cancer drug Jemperli was approved for an additional use, in first-line advanced and recurrent endometrial cancer (cancer of the womb lining), and real-world studies of Jemperli and Zejula began.3334
What the company expects
- On its earnings call of 3 Aug 2026, the company said it expects to launch Blenrep within 2 to 3 months, and that Blenrep, Ojjaara and Arexvy could launch potentially within 18 to 24 months; its documents give no later update.3536
- On its earnings call of 3 Aug 2026, the company said it expects to launch bepirovirsen, a possible functional cure (lasting control after treatment ends) for chronic hepatitis B, in India within 3 quarters if all goes well.37
- On its earnings call of 3 Aug 2026, the company said it expects EBITDA margins for the year at roughly last year's level, around 34%, as selling and administrative costs normalise.38
- On its earnings call of 3 Aug 2026, the company said its established general medicines and vaccines business needs to keep growing at 8% to 10%.39
Litigation and regulatory matters
- In its exchange filing of 6 Aug 2026, the company reported a final income-tax order with a ₹23.21 crore demand, a ₹52.00 crore refund for assessment year 1984-85 (the tax year assessed) and ₹42.09 crore of interest to be booked as income.40
- On 24 Jun 2026 the National Pharmaceutical Pricing Authority, the drug price regulator, demanded ₹3,54,12,025 for alleged overcharging, ₹1,22,91,163 plus ₹2,31,20,862 interest; the company said it would appeal and that there is no impact on its financial operations.41
Last updated
All 41 sources, each with its page
- 1. Annual report, 5 Jun 2026, page 30
- 2. Annual report, 5 Jun 2026, page 7
- 3. Annual report, 5 Jun 2026, page 40
- 4. Annual report, 5 Jun 2026, page 6
- 5. Annual report, 5 Jun 2026, page 71
- 6. Annual report, 5 Jun 2026, page 104
- 7. Annual report, 5 Jun 2026, page 134
- 8. Annual report, 5 Jun 2026, page 14
- 9. Annual report, 5 Jun 2026, page 72
- 10. Investor presentation, 3 Aug 2026, page 7
- 11. Earnings call, 3 Aug 2026, page 5
- 12. Investor presentation, 3 Aug 2026, page 7
- 13. Earnings call, 3 Aug 2026, page 6
- 14. Annual report, 5 Jun 2026, page 44
- 15. Annual report, 5 Jun 2026, page 44
- 16. Annual report, 5 Jun 2026, page 14
- 17. Investor presentation, 3 Aug 2026, page 5
- 18. Annual report, 5 Jun 2026, page 32
- 19. Annual report, 5 Jun 2026, page 14
- 20. Annual report, 5 Jun 2026, page 33
- 21. Investor presentation, 3 Aug 2026, page 7
- 22. Annual report, 5 Jun 2026, page 44
- 23. Earnings call, 3 Aug 2026, page 16
- 24. Annual report, 5 Jun 2026, page 40
- 25. Annual report, 5 Jun 2026, page 14
- 26. Annual report, 5 Jun 2026, page 18
- 27. Earnings call, 3 Aug 2026, page 11
- 28. Earnings call, 3 Aug 2026, page 13
- 29. Annual report, 5 Jun 2026, page 7
- 30. Annual report, 5 Jun 2026, page 18
- 31. Annual report, 5 Jun 2026, page 52
- 32. Earnings call, 3 Aug 2026, page 10
- 33. Annual report, 5 Jun 2026, page 54
- 34. Annual report, 5 Jun 2026, page 36
- 35. Earnings call, 3 Aug 2026, page 11
- 36. Earnings call, 3 Aug 2026, page 6
- 37. Earnings call, 3 Aug 2026, page 11
- 38. Earnings call, 3 Aug 2026, page 17
- 39. Earnings call, 3 Aug 2026, page 12
- 40. Exchange filing, 6 Aug 2026, page 1
- 41. Exchange filing, 25 Jun 2026, page 1
Results
Consolidated; ₹ crore.GlaxoSmithKline Pharmaceuticals quarterly results
- Revenue growth, 12 monthsRevenue growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +5.8%
- Net profit growth, 12 monthsNet profit growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +12.4%
Quarter to Jun 2026, against the quarter before
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹938 Crdown 5.71%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent. Net profit in the glossary
- ₹237 Crdown 14.64%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 25.3%
Revenue by quarter
Peak revenue ₹1,041 Cr, quarter to Dec 2025; lowest ₹805 Cr, quarter to Jun 2025
Net profit by quarter, a loss in red
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1,011 | 949 | 974 | 805 | 980 | 1,041 | 995 | 938 |
| Net profit | 253 | 230 | 263 | 205 | 257 | 296 | 278 | 237 |
| Net margin | 25.0% | 24.2% | 27.0% | 25.5% | 26.3% | 28.4% | 27.9% | 25.3% |
Consolidated. The last eight quarters. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Year to Mar 2026, against the year before
- RevenueRevenue. The pill is the change in revenue against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹3,822 Crup 1.93%
- Net profitNet profit. The pill is the change in net profit against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹1,036 Crup 11.69%
- Net margin
- 27.1%
Revenue by year
Net profit by year, a loss in red
The years either side of a change of basis do not compare. From the year to Mar 2022, the company's revenue for that year, ₹3,278 Cr, differs from its quarters added, ₹3,425 Cr; the company reports a discontinued business.
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3,000 | 2,896what Revenue, Mar 2018, includes. This period's revenue includes excise duty of ₹24 crore, a tax on the goods the company makes that it collects and pays to the government. | 3,128 | 3,224 | 3,199 | 3,278 | 3,252 | 3,454 | 3,749 | 3,822 |
| Net profit | 337 | 351 | 445 | 93 | 358 | 1,695 | 611 | 590 | 928 | 1,036 |
| Net margin | 11.2% | 12.1% | 14.2% | 2.9% | 11.2% | – | 18.8% | 17.1% | 24.7% | 27.1% |
Consolidated. Years to March. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share. Net margin is left blank for Mar 2022: the profit includes the result of a business the company has discontinued, which the revenue does not, so the two make no margin.
Business segments
In the year to Mar 2026 the company reports one business segment, Pharmaceuticals, which carries all its revenue.
Valuation
Today, against the company's own history. Its history crosses a change of basis in the accounts in the year to Mar 2022: days before it are of the company before the change.GlaxoSmithKline Pharmaceuticals PE ratio and valuation
Price to earnings
At or below today's level on 6% of 2,410 trading days over the last 10 years.
LowestHighest
Its median54.73Industry median27.98
Price to book
At or below today's level on 56% of 1,987 trading days since Oct 2018.
LowestHighest
Its median17.83Industry median2.94
Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.
At or below today's level on 77% of 2,473 trading days over the last 10 years.
LowestHighest
Its median1.79%Industry median0.48%
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −18.2% | +11.7% | −29.0% | 2.5% |
| 3 years | +21.9% | +19.3% | +0.5% | 2.0% |
| 5 years | +12.4% | +23.7% | −11.3% | 2.8% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth over 1, 3 and 5 years is on profit divided by shares in issue at both ends: the earnings per share stated for one end does not match that year's profit and share count. Earnings growth over 5 years includes one-off items (exceptional items and the result of businesses sold or closed) of more than a tenth of the profit of the year to Mar 2021.
Mutual fund holdings
137 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 71 of the 83 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future. 2 more funds filed their first portfolio on record, holding it.All 137 funds holding GlaxoSmithKline Pharmaceuticals
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 2
- Bought againBought again. Funds that held it at the month's end, had not held it the month before, and held it in an earlier month.
- 1
- AddedAdded. Funds that held more shares than at the end of the month before.
- 40
- CutCut. Funds that held fewer shares than at the end of the month before.
- 43
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 49
- Sold outSold out. Funds that held it at the end of the month before and hold none at this month's end. Sold out in the glossary
- 1
| Fund | |||
|---|---|---|---|
 SBI Midcap FundSBI Mutual Fund | 11,80,000 | 1.40% | ₹326.8 Cr |
 Kotak Large & Mid Cap FundKotak Mahindra Mutual Fund | 11,00,000 | 1.00% | ₹304.6 Cr |
 Nippon India Pharma FundNippon India Mutual Fund | 10,29,460 | 3.11% | ₹285.1 Cr |
 quant Mid Cap Fundquant Mutual Fund | 8,89,486 | 3.22% | ₹246.3 Cr |
| Nippon India Growth Mid Cap FundNippon India Mutual Fund | 5,59,000 | 0.31% | ₹154.8 Cr |
| SBI Dividend Yield FundSBI Mutual Fund | 4,50,000 | 1.55% | ₹124.6 Cr |
 Bandhan Large & Mid Cap FundBandhan Mutual Fund | 3,47,860 | 0.47% | ₹96.3 Cr |
 Bajaj Finserv Flexi Cap FundBajaj Finserv Mutual Fund | 3,35,705 | 1.09% | ₹93.0 Cr |
| Bandhan ELSS - Tax Saver FundBandhan Mutual Fund | 2,75,000 | 1.15% | ₹76.2 Cr |
 Tata Aggressive Hybrid FundTata Mutual Fund | 2,50,000 | 1.74% | ₹69.2 Cr |
Portfolios disclosed for Sep 2026. Weight is the holding as a share of the fund's assets.
GlaxoSmithKline Pharmaceuticals competitors and peers
Pharmaceuticals, 215 listed companies, priced on 28 Oct 2026. The table lists the 8 companies closest to GlaxoSmithKline Pharmaceuticals in market cap.Healthcare companies
Where the company sits among the companies nearest its size
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Abbott IndiaABBOTINDIA | 55,833 | 34.58 | 11.69 | +6.3% | +11.2% | 35.9% | 39.6% | 2.50% |
 Gland PharmaGLAND | 50,312 | 44.57 | 4.86 | +17.6% | +46.5% | 11.6% | 12.4% | 0.66% |
 IPCA LaboratoriesIPCALAB | 48,978 | 37.39 | 6.07 | +10.6% | +68.2% | 17.4% | 17.6% | 0.31% |
 Ajanta PharmaAJANTPHARM | 43,233 | 38.10 | 9.55 | +20.2% | +22.0% | 27.3% | 27.2% | 1.73% |
 Emcure PharmaceuticalsEMCURE | 35,571 | 35.17 | 7.19 | +18.4% | +35.9% | 21.5% | 25.2% | 0.19% |
 Sai Life SciencesSAILIFE | 31,591 | 87.33 | 12.72 | – | – | 15.7% | 18.7% | 0.00% |
 WockhardtWOCKPHARMA | 31,091 | 76.02 | 6.29 | +18.4% | – | 8.8% | 7.4% | 0.00% |
 Piramal PharmaPPLPHARMA | 30,994 | – | 3.81 | +9.4% | – | −2.6% | 2.3% | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Dividends
Per share, by the year it was paid for, and the latest payments.GlaxoSmithKline Pharmaceuticals dividend history
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up. Dividend per share in the glossaryHighest ₹90.00 a share, year to Mar 2022.
| Ex-date | Type | Per share |
|---|---|---|
| 29 May 2026 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. Final dividend in the glossary | ₹57.00 |
| 30 May 2025 | Final | ₹42.00 |
| 7 Nov 2024 | Interim | ₹12.00 |
| 31 May 2024 | Final | ₹32.00 |
| 30 Jun 2023 | Final | ₹32.00 |
| 7 Jul 2022 | Final | ₹30.00 |
Latest payments, as declared, by ex-date.
Latest announcements
Routine notices left out.GlaxoSmithKline Pharmaceuticals announcements
Oct 2026
28 Oct · Analysts
13 Oct · Updates
13 Oct · Board meeting
Sep 2026
2 Sep · Meeting
Aug 2026
26 Aug · Volume Movement Letter
GlaxoSmithKline Pharmaceuticals annual report, year to Mar 2026
GlaxoSmithKline Pharmaceuticals share price by year
Each calendar year to 2025.GlaxoSmithKline Pharmaceuticals share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 2,473.60 | +9.8% | 3,466.20 | 1,956.20 |
| 2024 | 2,251.85 | +18.6% | 3,061.45 | 1,871.20 |
| 2023 | 1,898.15 | +43.9% | 1,898.15 | 1,230.60 |
| 2022 | 1,318.75 | −24.9% | 1,773.75 | 1,300.45 |
| 2021 | 1,756.65 | +8.2% | 1,882.60 | 1,401.55 |
| 2020 | 1,623.95 | +0.8% | 1,778.60 | 1,101.85 |
| 2019 | 1,610.30 | +6.3% | 1,697.65 | 1,140.05 |
| 2018 | 1,515.35 | +21.7% | 1,795.05 | 1,043.88 |
| 2017 | 1,244.65 | −8.8% | 1,380.60 | 1,165.28 |
| 2016 | 1,364.90 | −17.6% | 1,907.38 | 1,305.05 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before.
Recent sessions
The 9 trading days to 27 Oct 2026, as traded on NSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 27 Oct 2026 | 2,435.30 | 2,518.50 | 2,435.30 | 2,472.40 | 2,477.28 | 89,270 | 74.5% |
| 26 Oct 2026 | 2,400.00 | 2,453.80 | 2,398.10 | 2,445.90 | 2,432.97 | 18,515 | 52.0% |
| 23 Oct 2026 | 2,432.80 | 2,432.80 | 2,344.10 | 2,404.70 | 2,390.68 | 56,174 | 58.6% |
| 22 Oct 2026 | 2,460.00 | 2,464.60 | 2,422.20 | 2,433.70 | 2,436.82 | 22,943 | 52.2% |
| 21 Oct 2026 | 2,460.00 | 2,517.90 | 2,445.00 | 2,464.40 | 2,470.00 | 27,689 | 44.6% |
| 19 Oct 2026 | 2,555.10 | 2,555.20 | 2,473.30 | 2,495.40 | 2,502.72 | 21,147 | 51.8% |
| 16 Oct 2026 | 2,530.00 | 2,573.20 | 2,518.40 | 2,566.10 | 2,556.74 | 61,686 | 54.7% |
| 15 Oct 2026 | 2,538.00 | 2,538.00 | 2,491.20 | 2,524.70 | 2,515.95 | 45,439 | 57.2% |
| 14 Oct 2026 | 2,536.30 | 2,548.30 | 2,502.00 | 2,538.90 | 2,527.86 | 41,627 | 44.1% |
Prices in ₹ per share as traded, not adjusted.
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Bonus share history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 11 Sep 2018 | Bonus | 0.5000 | Holders received 1 bonus share for every 1 held. |
Earlier prices are multiplied by the factor, so the chart reads as one share held throughout.
Company details
- NSE symbol
- GLAXO
- BSE code
- 500660
- ISIN
- INE159A01016
- Industry
- Pharmaceuticals & Biotechnology
- Website
- www.gsk-india.com
- CIN
- L24239MH1924PLC001151
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 1924
- Registered office
- GSK House, Dr Annie Besant Road, Worli, Mumbai 400030, Maharashtra
- Share registrar
- KFin Technologies Ltd
- Keeps the register of shareholders and handles transfers and dividend payments
In BSE 200, Nifty 500, BSE 500, Nifty Midcap 150, BSE 150 MidCap Index, BSE MidCap